A phase II study of first-line single agent of gefitinib in patients (pts) with stage IV non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Suzuki, R [1 ]
Hasegawa, Y [1 ]
Baba, K [1 ]
Saka, H [1 ]
Saito, H [1 ]
Taniguchi, H [1 ]
Yamamoto, M [1 ]
Matsumoto, S [1 ]
Kato, K [1 ]
Shimokata, K [1 ]
机构：
[1] Cent Japan Lung Study Grp, Nagoya, Aichi, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：640S / 640S
页数：1
相关论文
共 50 条
  • [31] A phase I/II trial of weekly docetaxel and gefitinib in elderly patients (≥70) with stage IIIB/IV non-small cell lung cancer (NSCLC)
    Stinchcombe, T
    Socinski, M
    Choksi, J
    Bakri, K
    Taylor, M
    Tynan, M
    Mears, A
    Smith, C
    [J]. LUNG CANCER, 2005, 49 : S270 - S270
  • [32] A phase I/II trial of weekly docetaxel and gefitinib in elderly patients (≥ 70) with stage IIIB/IV non-small cell lung cancer (NSCLC).
    Stinchcombe, TE
    Socinski, MA
    Choksi, J
    Bakri, K
    Taylor, M
    Tynan, MT
    Mears, A
    Smith, C
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 685S - 685S
  • [33] Survival outcome segregated by KRAS mutation status in newly diagnosed stage IV non-small cell lung cancer (NSCLC) patients (pts) treated with first-line chemotherapy
    Brady, Anna K.
    McNeill, Jonathan D.
    Judy, Brendan
    Evans, Tracey L.
    Cohen, Roger B.
    Langer, Corey J.
    Vachani, Anil
    Aggarwal, Charu
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [34] Non-Cross Resistant Sequential Single Agent Chemotherapy in First-Line Advanced Non-Small Cell Lung Cancer Patients: Results of a Phase II Study
    Surmont, V.
    Aerts, J. G. J. V.
    Tan, K. Y.
    Schramel, F.
    Vernhout, R.
    Hoogsteden, H. C.
    van Klaveren, R. J.
    [J]. JOURNAL OF ONCOLOGY, 2009, 2009
  • [35] A FINAL RESULTS OF A PHASE II STUDY OF FIRST-LINE GEFITINIB FOR ELDERLY PATIENTS (PTS) WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS; NEJ 003 STUDY
    Inoue, A.
    Minegishi, Y.
    Maemondo, M.
    Okinaga, S.
    Morikawa, N.
    Kobayashi, K.
    Harada, M.
    Hagiwara, K.
    Nukiwa, T.
    Gemma, A.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : 141 - 142
  • [36] GEFITINIB (G) AND PEMETREXED (PEM) AS A FIRST LINE TREATMENT IN PATIENTS WITH EGFR MUTANT ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): A PHASE II STUDY
    Yoshimura, N.
    Matsuura, K.
    Mitsuoka, S.
    Asai, K.
    Tochino, Y.
    Kimura, T.
    Nakai, M.
    Mitsukawa, Y.
    Hirata, K.
    Kudoh, S.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 412 - 413
  • [37] Oral vinorelbine as single-agent first-line treatment in elderly patients (pts) with advanced non-small-cell lung cancer (NSCLC)
    Mendez, M.
    Andrade, J.
    Esquerdo, G.
    Morales, S.
    Garcia-Gomez, R.
    Garcia-Bueno, J. M.
    Blancas, I.
    Trujillo, R.
    Juarez, J. I.
    Gayo, J.
    [J]. EJC SUPPLEMENTS, 2007, 5 (04): : 389 - 389
  • [38] Results of a phase I/II trial of carboplatin/gemcitabine plus celecoxib for first-line treatment of stage IIIB/IV non-small cell lung cancer (NSCLC).
    Burton, JD
    El-Sayah, D
    Cherry, M
    Bhargava, M
    Terjanian, T
    Odaimi, M
    Vesoniaraki, M
    Lowry, J
    Forte, F
    Friscia, P
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 682S - 682S
  • [39] FAST-ACT: A phase II randomized double-blind trial of sequential erlotinib and chemotherapy as first-line treatment in patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC)
    Lee, J. S.
    Ignacio, J.
    Yu, C.
    Zhou, C.
    Wu, Y.
    Chen, Y.
    Zhang, L.
    Jin, K.
    Johnston, M.
    Mok, T. S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [40] Analysis of optimal timing of gefitinib in sensitive non-small cell lung cancer (NSCLC) patients: Should we use gefitinib as first-line chemotherapy?
    Kenmotsu, H.
    Goto, K.
    Naito, Y.
    Nishiwaki, Y.
    Kubota, K.
    Ohmatsu, H.
    Niho, S.
    Yoh, K.
    Nagai, K.
    Saijo, N.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345